<DOC>
	<DOCNO>NCT01306786</DOCNO>
	<brief_summary>The aim randomize trial compare efficacy tolerability H. pylori eradication 5-day quadruple therapy versus clarithromycin-containing triple therapy .</brief_summary>
	<brief_title>Five Days Quadruple Clarithromycin Containing Triple Therapy Treatment Helicobacter Pylori Eradication</brief_title>
	<detailed_description>Eligible patient H pylori infection randomize receive either five-day QUAD ( esomeprazole 20mg b.d. , bismuth subcitrate 120mg q.i.d. , tetracycline 250mg q.i.d . metronidazole 250mg q.i.d . ) EAC ( esomeprazole 20mg b.d. , amoxicillin 1g b.d . clarithromycin 500mg b.d. ) . H. pylori status rechecked 13C urea breath test 8 week treatment . Patients fail respective therapy invite undergo H. pylorus susceptibility test crossover receive alternative regimen duration .</detailed_description>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Bismuth</mesh_term>
	<mesh_term>Bismuth tripotassium dicitrate</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>patient H. pylori infection receive H. pylorus eradication therapy patient receive previous H. pylorus eradication therapy comorbidity liver cirrhosis comorbidity renal failure comorbidity alcoholism comorbidity malignancy receive antibiotic , bismuth preparation , proton pump inhibitor probiotic precede three month patient know allergy medication use patient history previous gastrointestinal disease gastric surgery pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>